FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis.
CT perfusion
Colorectal cancer
FDG-PET
Metabolism
Survival
Vascular
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
28
10
2020
accepted:
13
03
2021
pubmed:
11
4
2021
medline:
3
2
2022
entrez:
10
4
2021
Statut:
ppublish
Résumé
This study assesses the potential for vascular-metabolic imaging with FluoroDeoxyGlucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT) perfusion to provide markers of prognosis specific to the site and stage of colorectal cancer. This prospective observational study comprised of participants with suspected colorectal cancer categorized as either (a) non-metastatic colon cancer (M0colon), (b) non-metastatic rectal cancer (M0rectum), or (c) metastatic colorectal cancer (M+). Combined FDG-PET/CT perfusion imaging was successfully performed in 286 participants (184 males, 102 females, age: 69.60 ± 10 years) deriving vascular and metabolic imaging parameters. Vascular and metabolic imaging parameters alone and in combination were investigated with respect to overall survival. A vascular-metabolic signature that was significantly associated with poorer survival was identified for each patient group: M0colon - high Total Lesion Glycolysis (TLG) with increased Permeability Surface Area Product/Blood Flow (PS/BF), Hazard Ratio (HR) 3.472 (95% CI: 1.441-8.333), p = 0.006; M0rectum - high Metabolic Tumour Volume (MTV) with increased PS/BF, HR 4.567 (95% CI: 1.901-10.970), p = 0.001; M+ participants, high MTV with longer Time To Peak (TTP) enhancement, HR 2.421 (95% CI: 1.162-5.045), p = 0.018. In participants with stage 2 colon cancer as well as those with stage 3 rectal cancer, the vascular-metabolic signature could stratify the prognosis of these participants. Vascular and metabolic imaging using FDG-PET/CT can be used to synergise prognostic markers. The hazard ratios suggest that the technique may have clinical utility.
Identifiants
pubmed: 33837843
doi: 10.1007/s00259-021-05318-y
pii: 10.1007/s00259-021-05318-y
pmc: PMC8712298
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-384Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
J Mol Diagn. 2009 Nov;11(6):543-52
pubmed: 19815694
Dis Colon Rectum. 2013 Jan;56(1):43-50
pubmed: 23222279
Br J Radiol. 2012 Oct;85(1018):e814-25
pubmed: 22514101
J Dig Dis. 2012 Jan;13(1):24-32
pubmed: 22188913
J Surg Oncol. 2013 Sep;108(4):220-4
pubmed: 23893480
Clin Imaging. 2012 Nov-Dec;36(6):754-7
pubmed: 23154005
J Glob Oncol. 2019 Feb;5:1-19
pubmed: 30802158
Eur Radiol. 2009 Jan;19(1):79-89
pubmed: 18704434
Gastroenterol Res Pract. 2018 Jun 13;2018:2397863
pubmed: 30008744
J Clin Oncol. 2009 Jun 20;27(18):3020-6
pubmed: 19470921
J Thorac Dis. 2013 Sep;5 Suppl 4:S383-8
pubmed: 24102011
Dis Colon Rectum. 2009 Sep;52(9):1624-9
pubmed: 19690492
J Nucl Med. 2012 May;53(5):687-92
pubmed: 22454485
PLoS One. 2019 Dec 27;14(12):e0219724
pubmed: 31881020
Radiology. 2007 Aug;244(2):486-93
pubmed: 17641369
Stat Med. 1996 Oct 30;15(20):2203-13
pubmed: 8910964
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
AJR Am J Roentgenol. 2005 Jul;185(1):225-31
pubmed: 15972428
Acad Radiol. 2015 Dec;22(12):1529-35
pubmed: 26421473
Eur Radiol. 2012 Jul;22(7):1430-41
pubmed: 22367468
BMC Cancer. 2015 Dec 21;15:991
pubmed: 26689966
Ann Nucl Med. 2019 Jan;33(1):32-38
pubmed: 30218280
Eur J Surg Oncol. 2002 Jun;28(4):418-23
pubmed: 12099653
Br J Cancer. 2006 Jun 19;94(12):1823-32
pubmed: 16773076
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
PLoS One. 2016 May 31;11(5):e0156665
pubmed: 27243824
Acad Radiol. 2014 Jun;21(6):750-7
pubmed: 24809317
J Clin Pathol. 2007 Aug;60(8):912-5
pubmed: 16997919
Ann Oncol. 2011 Mar;22(3):739-745
pubmed: 20813876
World J Gastroenterol. 2013 Dec 14;19(46):8502-14
pubmed: 24379567
Clin Nucl Med. 2015 Dec;40(12):930-5
pubmed: 26204222
BMJ. 2020 Mar 2;368:m461
pubmed: 32122877
Cancer Imaging. 2015 Nov 20;15:19
pubmed: 26589835
Ann Surg. 2011 Apr;253(4):666-71
pubmed: 21475005
Curr Oncol. 2013 Jun;20(3):e255-65
pubmed: 23737695
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancer Imaging. 2012 Sep 28;12:336-44
pubmed: 23023069
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Nucl Med. 2016 Oct;41(10):761-5
pubmed: 27556789